PeopleBeatingCancer

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Learn More

Gut Microbiome, CAR-T, Myeloma

Share Button

Can the gut microbiome influence  CAR-T therapy for myeloma? According to the study linked below,  bacterial diversity in your gut enhances your response to CAR-T therapy.

This finding really shouldn’t be a surprise. The gut microbiome influences many aspects of cancer.

How changes in the gut microbiome may impact patient response to CAR-T therapy

How many aspects of cancer are influenced by the cancer patient’s gut microbiome?

The gut microbiome plays a significant and multifaceted role in cancer. Research has shown that the microbiome can influence at least five major aspects of cancer in a patient:

1. Cancer Development (Carcinogenesis)

  • Certain microbial species can produce toxins, inflammatory molecules, or metabolites that promote DNA damage, chronic inflammation, and oncogenesis.

  • Example: Fusobacterium nucleatum is associated with colorectal cancer due to its pro-inflammatory and pro-oncogenic activity.

2. Tumor Progression and Metastasis

  • The microbiome can modulate immune responses and alter the tumor microenvironment, promoting or inhibiting tumor growth and spread.

  • Microbial products like short-chain fatty acids (SCFAs) or bile acid metabolites can affect cancer cell behavior.

3. Response to Cancer Therapy

  • Chemotherapy: The gut microbiome affects drug metabolism and toxicity. For instance, Enterococcus hirae and Barnesiella intestinihominis enhance the efficacy of cyclophosphamide.

  • Immunotherapy: Response to immune checkpoint inhibitors (e.g., anti-PD-1) is influenced by gut microbiome composition—patients with beneficial microbes like Akkermansia muciniphila show better responses.

  • Radiotherapy: Gut dysbiosis can worsen side effects and reduce treatment efficacy.

4. Toxicity and Side Effects of Treatment

  • Microbial metabolism can produce compounds that either protect against or exacerbate treatment-related toxicities.

  • Example: Irinotecan-induced diarrhea is worsened by bacterial β-glucuronidase activity.

5. Prognosis and Survival

  • The microbiome can be a biomarker for prognosis. Certain microbial profiles are associated with longer survival or reduced relapse.

  • Fecal microbiota composition can predict disease-free survival in some cancers.

Emerging and Related Aspects

  • Microbiome-based therapies: Fecal microbiota transplantation (FMT), probiotics, and prebiotics are being investigated as adjuncts to improve cancer treatment outcomes.

  • Nutritional modulation: Diet-induced microbiome changes can affect cancer risk and treatment.

Summary

At least five key aspects of cancer—development, progression, therapy response, side effects, and prognosis—are influenced by the gut microbiome. Ongoing research continues to uncover even more complex interactions, suggesting that the microbiome is a critical factor in personalized oncology.

I am a long-term myeloma survivor. Are you a multiple myeloma survivor? Are you considering CAR-T cell therapy? Email me at David.PeopleBeatingCancer@gmail.com with your questions about both conventional and non-conventional therapies.

Good luck,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

The Most Heavily Trafficked Myeloma Blog posts on PeopleBeatingCancer.org

  1. Multiple Myeloma- Need to Know
  2. Tom Brokaw, Celebrities, Survivor Stories –
  3. The Multiple Myeloma Coaching Course 
  4. Gut Microbiome, CAR-T, Myeloma
  5. Long-Term Myeloma Survivor: I Wish I Knew then…

Below is a 7-day nutrition plan designed specifically for a multiple myeloma patient preparing for CAR-T cell therapy. This focuses on:

  • Supporting immune resilience before lymphodepleting chemotherapy and CAR-T infusion

  • Supporting gut microbiome diversity (important for immunotherapy outcomes)

  • Maintaining muscle mass and protein intake

  • Minimizing infection risk (food safety is critical during treatment)

  • Supporting energy and blood count recovery

  • Managing inflammation and oxidative stress

This is general educational guidance and should always be cleared with the oncology team, especially because CAR-T patients may require temporary neutropenic diet restrictions.

7-Day Diet Plan for Myeloma Patient Preparing for CAR-T Therapy

Core Nutrition Goals

Protein

  • Target: ~1.2–1.5 g/kg body weight daily

  • Helps maintain muscle, immune function, and treatment recovery

Microbiome Support

  • Fiber from vegetables, legumes, whole grains

  • Fermented foods (if allowed by care team)

Anti-Inflammatory Focus

  • Omega-3 fats

  • Polyphenols (berries, green tea, spices)

Hydration

  • 2–3 liters daily unless fluid restricted

Food Safety (Very Important)

  • Wash produce thoroughly

  • Avoid raw seafood or undercooked eggs/meat

  • Avoid unpasteurized dairy

  • Refrigerate leftovers promptly

Day 1

Breakfast

  • Steel-cut oatmeal

  • Blueberries and ground flaxseed

  • Greek yogurt (pasteurized)

Snack

  • Apple slices with almond butter

Lunch

  • Grilled wild salmon

  • Quinoa

  • Steamed broccoli

  • Olive oil drizzle

Snack

  • Kefir smoothie with banana and cinnamon

Dinner

  • Baked chicken breast

  • Roasted sweet potato

  • Sautéed spinach and garlic

Day 2

Breakfast

  • Vegetable omelet (spinach, mushrooms, peppers)

  • Whole grain toast

  • Green tea

Snack

  • Cottage cheese with pineapple

Lunch

  • Lentil soup

  • Mixed greens salad with olive oil and lemon

  • Whole grain crackers

Snack

  • Walnuts and pear

Dinner

  • Turkey meatballs

  • Brown rice

  • Roasted Brussels sprouts

Day 3

Breakfast

  • Smoothie:

    • Protein powder (oncology-approved)

    • Frozen berries

    • Spinach

    • Unsweetened almond milk

    • Chia seeds

Snack

  • Hard-boiled eggs

Lunch

  • Sardine and avocado whole-grain wrap

  • Carrot and cucumber sticks

Snack

  • Plain yogurt with honey and turmeric

Dinner

  • Grass-fed beef stir-fry

  • Bok choy

  • Brown rice noodles

Day 4

Breakfast

  • Overnight oats with:

    • Pumpkin seeds

    • Strawberries

    • Cinnamon

Snack

  • Hummus with bell peppers

Lunch

  • Grilled chicken salad with:

    • Arugula

    • Cherry tomatoes

    • Avocado

    • Olive oil vinaigrette

Snack

  • Banana with peanut butter

Dinner

  • Baked cod

  • Barley

  • Steamed asparagus

Day 5

Breakfast

  • Scrambled eggs

  • Sautéed kale

  • Whole grain English muffin

Snack

  • Smoothie with kefir, mango, and flaxseed

Lunch

  • Black bean and vegetable bowl

  • Brown rice

  • Guacamole

Snack

  • Trail mix (almonds, pumpkin seeds, dried cranberries)

Dinner

  • Herb-roasted turkey breast

  • Mashed cauliflower

  • Green beans

Day 6

Breakfast

  • Buckwheat pancakes

  • Fresh raspberries

  • Plain yogurt topping

Snack

  • Protein shake

Lunch

  • Tuna salad with olive oil mayonnaise

  • Whole grain pita

  • Mixed vegetable soup

Snack

  • Edamame

Dinner

  • Baked tofu or grilled chicken

  • Quinoa pilaf

  • Roasted zucchini

Day 7

Breakfast

  • Chia pudding with almond milk and blueberries

Snack

  • Apple and walnuts

Lunch

  • Minestrone soup with beans and vegetables

  • Whole grain bread

Snack

  • Cottage cheese with berries

Dinner

  • Grilled shrimp or baked salmon

  • Farro

  • Roasted carrots and parsnips

Helpful CAR-T Preparation Nutrition Tips

1. Support the Microbiome

Research suggests gut diversity may influence CAR-T and immunotherapy response.

Helpful foods:

  • Yogurt or kefir (pasteurized)

  • Fiber-rich vegetables

  • Beans and legumes

  • Whole grains

  • Fermented vegetables (if approved)

2. Maintain Protein Intake During Fatigue

If appetite drops:

  • Smoothies

  • Soups with protein added

  • Protein shakes

  • Nut butters

  • Greek yogurt

3. Manage Treatment Side Effects

If Nausea Occurs

  • Ginger tea

  • Small frequent meals

  • Bland foods (rice, bananas, toast)

If Mouth Sores Occur

  • Soft foods

  • Avoid acidic or spicy foods

  • Smoothies and soups

4. Supplements to Discuss with Oncology Team

(Some may interact with therapy.)

Often considered:

  • Vitamin D

  • Omega-3 fatty acids

  • Probiotics (case-by-case)

  • Magnesium

5. Foods Often Limited During CAR-T and Neutropenia

  • Raw sushi or shellfish

  • Raw eggs

  • Deli meats unless heated

  • Unwashed produce

  • Unpasteurized dairy

Sample Daily Hydration Plan

  • Morning: Warm water with lemon

  • Throughout day: Water or electrolyte drink

  • Optional: Green tea or ginger tea

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

  • Major microbiome disruption was associated with toxicities following ide-cel administration in patients with multiple myeloma.
  • Bacterial diversity decreased post-ide-cel infusion and bacterial composition was associated with ide-cel response and toxicities.
Increasing evidence suggests that the gut microbiome may influence the responses and toxicities associated with chimeric antigen receptor (CAR) therapy. We conducted whole-genome shotgun sequencing on stool samples (n=117) collected at various times from multiple myeloma patients (n=33) undergoing idecabtagene vicleucel (ide-cel) anti-B cell maturation antigen CAR-T therapy.We observed a significant decrease in bacterial diversity post-ide-cel infusion, along with significant differences in bacterial composition linked to therapy response and toxicities. Specifically, we found significant enrichment of

  • Flavonifractor plautii,
  • Bacteroides thetaiotaomicron,
  • Blautia fecis,
  • and Dysosmobacter species

in ide-cel responders. A notable finding was the link between major microbiome disruption, defined as dominant specific taxa (greater than 35% prevalence) and increased facultative pathobionts like Enterococcus, with ide-cel toxicities, especially cytokine release syndrome (CRS).

Patients with genus dominance in baseline samples had a higher incidence of grade 2 or higher CRS at 46.2% compared to those without genus dominance (11.1%, p=0.043).

Additionally, network analysis and mass spectrometric assessment of stool metabolites revealed important associations and pathways, such as Flavonifractor plautii being linked to increased indole metabolites and pathways in responders.

Our findings uncover novel microbiome associations between ide-cel responses and toxicities that may be useful for developing modalities to improve CAR-T outcomes.

gut microbiome  CAR-T myeloma gut microbiome  CAR-T myeloma gut microbiome  CAR-T myeloma

Leave a Comment:

Popular posts

Multiple Myeloma Diet
 Multiple Myeloma Multiple Myeloma Diet
Feb 15, 2022
Multiple Myeloma Second Opinion: 7 Questions Every Newly Diagnosed Patient Should Ask
 Multiple Myeloma
Nov 04, 2022
C-B-D Enhances Velcade (BORT)
 integrative therapy Multiple Myeloma
Aug 07, 2022
Can Endometrial Polyps Become Cancer? What Women Need to Know
 Endometrial Cancer
Nov 14, 2021